AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39760239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape stripping combined with high-throughput RNA sequencing
Number of subjects: 66
Study 39760239 — intervention group
Group type: COMPARATOR
Intervention: Tape stripping
Number of subjects: 66
Study 39760302 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D acoustic radiation force impulse (ARFI) imaging for targeted prostate biopsy guidance
Number of subjects: 0
Study 39760302 — intervention group
Group type: COMPARATOR
Intervention: Multiparametric magnetic resonance imaging (mpMRI)-ultrasound fusion TP biopsy
Number of subjects: 0
Study 39760302 — intervention group
Group type: COMPARATOR
Intervention: Systematic sampling TP biopsy
Number of subjects: 0
Study 39760815 — intervention group
Group type: EXPERIMENTAL
Intervention: AL2846 combined with gemcitabine (90 mg and 120 mg)
Number of subjects: 33
Study 39760815 — intervention group
Group type: EXPERIMENTAL
Intervention: AL2846 combined with gemcitabine
Number of subjects: 33
Study 39760981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 47
Study 39760981 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 47
Study 39760983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% applied twice daily for 4 weeks, then as needed up to 52 weeks
Number of subjects: 29
Study 39761005 — intervention group
Group type: EXPERIMENTAL
Intervention: hSAP (12.5 μg/g)
Number of subjects: 0
Study 39761016 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated group (107 infants)
Number of subjects: 223
Study 39761016 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated group (116 infants)
Number of subjects: 223
Study 39761016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 223
Study 39761063 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-071
Number of subjects: 54
Study 39761063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 39761213 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care intervention
Number of subjects: 0
Study 39761213 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39761305 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 100
Study 39761305 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent Training (MT)
Number of subjects: 100
Study 39761305 — intervention group
Group type: COMPARATOR
Intervention: No Exercise Group
Number of subjects: 100
Study 39761361 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based pain assessment application
Number of subjects: 68
Study 39761361 — intervention group
Group type: COMPARATOR
Intervention: Nurses' pain assessment
Number of subjects: 68
Study 39761483 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg once every 3 weeks
Number of subjects: 137
Study 39761483 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd)
Number of subjects: 137
Study 39761550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for monitoring (AppO2) in addition to conventional monitoring
Number of subjects: 45
Study 39761550 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring only
Number of subjects: 45
Study 39761592 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 250
Study 39761592 — intervention group
Group type: COMPARATOR
Intervention: Control (no amlodipine unless two BP ≥140/90 mmHg)
Number of subjects: 250
Study 39761695 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS IH (severe MPS I)
Number of subjects: 71
Study 39761695 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS IA (attenuated MPS I)
Number of subjects: 71
Study 39761695 — intervention group
Group type: COMPARATOR
Intervention: MPS IH
Number of subjects: 71
Study 39761695 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS IA
Number of subjects: 71
Study 39761695 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS IH and MPS IA
Number of subjects: 71
Study 39761745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable-polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 2350
Study 39761745 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stent
Number of subjects: 2350
Study 39761745 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe tortuosity
Number of subjects: 2350
Study 39761829 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg daily
Number of subjects: 80
Study 39761829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 39762092 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch ECG (ECG247 Smart Heart Sensor)
Number of subjects: 14
Study 39762092 — intervention group
Group type: COMPARATOR
Intervention: Insertable cardiac monitor (Confirm Rx, Abbott)
Number of subjects: 14
Study 39762097 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based self-management fall prevention intervention (eight 2-hour online synchronous sessions facilitated by a licensed healthcare professional)
Number of subjects: 240
Study 39762097 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard MS care and rehabilitation plus a brochure on fall risk factors and fall prevention)
Number of subjects: 240
Study 39762098 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg omalizumab administered subcutaneously every 4 weeks (Q4W) for 36 weeks
Number of subjects: 0
Study 39762098 — intervention group
Group type: COMPARATOR
Intervention: 300 mg omalizumab administered subcutaneously every 6 weeks (Q6W) for 36 weeks
Number of subjects: 0
Study 39762098 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples, Weekly Urticaria Activity Score, Chronic Urticaria Quality of Life Questionnaire, Dermatology Life Quality Index
Number of subjects: 0
Study 39762099 — intervention group
Group type: EXPERIMENTAL
Intervention: hEDS group
Number of subjects: 282
Study 39762099 — intervention group
Group type: COMPARATOR
Intervention: MFS group
Number of subjects: 282
Study 39762099 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 282
Study 39762105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP)
Number of subjects: 739
Study 39762113 — intervention group
Group type: EXPERIMENTAL
Intervention: EIMG (Exercise is Medicine Greenville) intervention with a standardised instructional video and a 12-week evidence-informed physical activity programme.
Number of subjects: 20
Study 39762113 — intervention group
Group type: EXPERIMENTAL
Intervention: EIMG onboard training for adopting clinics in Phase II.
Number of subjects: 20
Study 39762111 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 58
Study 39762111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 39762123 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 76
Study 39762160 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) conversations
Number of subjects: 29
Study 39762230 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent pen
Number of subjects: 20
Study 39762230 — intervention group
Group type: EXPERIMENTAL
Intervention: VistaCam iX
Number of subjects: 20
Study 39762230 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-tactile method
Number of subjects: 20
Study 39762248 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-270/S095033 (oral, potent, reversible inhibitor of MAT2A) administered once daily (QD) or twice daily (BID) in 28-day cycles.
Number of subjects: 40
Study 39762316 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyfe CoughMonitor wrist-worn device
Number of subjects: 546
Study 39762418 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment group A)
Number of subjects: 186
Study 39762418 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment group B)
Number of subjects: 186
Study 39762418 — intervention group
Group type: COMPARATOR
Intervention: neoadjuvant chemoradiation alone (control group)
Number of subjects: 186
Study 39762419 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecirasib (JAB-21822) administered orally at 800 mg daily
Number of subjects: 0
Study 39762421 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 33
Study 39762422 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran monotherapy
Number of subjects: 213
Study 39762422 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran with atezolizumab
Number of subjects: 213
Study 39762494 — intervention group
Group type: EXPERIMENTAL
Intervention: NELIP + FBBT
Number of subjects: 116
Study 39762494 — intervention group
Group type: COMPARATOR
Intervention: NELIP
Number of subjects: 116
Study 39762691 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of physical activity
Number of subjects: 0
Study 39762691 — intervention group
Group type: COMPARATOR
Intervention: Low levels of physical activity
Number of subjects: 0
Study 39762740 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg orally disintegrating tablet
Number of subjects: 103
Study 39762827 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic habit reminder (wristwatch with alarming sound)
Number of subjects: 22
Study 39762827 — intervention group
Group type: COMPARATOR
Intervention: Palatal crib
Number of subjects: 22
Study 39762827 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic habit reminder
Number of subjects: 22
Study 39762831 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lung cancer
Number of subjects: 254
Study 39762831 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of lung cancer patients
Number of subjects: 254
Study 39762831 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' illness perception
Number of subjects: 254
Study 39762831 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' mindfulness and self-compassion levels
Number of subjects: 254
Study 39762831 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' level of illness perception and number of other caregivers
Number of subjects: 254
Study 39762831 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' dyadic coping level, residence, and self-compassion level
Number of subjects: 254
Study 39762850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-modified scan body (TMSB)
Number of subjects: 6
Study 39762850 — intervention group
Group type: COMPARATOR
Intervention: Conventional scan body (CSB)
Number of subjects: 6
Study 39762879 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid vaginal gel applied for 12 days
Number of subjects: 32
Study 39762879 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole 500 mg twice daily for seven days
Number of subjects: 32
Study 39762887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutrition intervention (EN and supplemental PN)
Number of subjects: 237
Study 39762887 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237
Study 39762887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutrition intervention
Number of subjects: 237
Study 39762915 — intervention group
Group type: EXPERIMENTAL
Intervention: DV-U montage (cathode over T11/T12, anodes over umbilicus)
Number of subjects: 15
Study 39762915 — intervention group
Group type: EXPERIMENTAL
Intervention: DV-I montage (cathode over T11/T12, anodes over iliac crests)
Number of subjects: 15
Study 39762915 — intervention group
Group type: COMPARATOR
Intervention: DV-PU montage (cathode over T11/T12, anodes over umbilicus)
Number of subjects: 15
Study 39762915 — intervention group
Group type: COMPARATOR
Intervention: DV-PI montage (dual paraspinal cathodes at T11/12, anodes over iliac crests)
Number of subjects: 15
Study 39762915 — intervention group
Group type: COMPARATOR
Intervention: DM-C montage (cathode over T11/12, anode 5 cm caudal)
Number of subjects: 15
Study 39762915 — intervention group
Group type: COMPARATOR
Intervention: DM-R montage (cathode over T11/12, anode 5 cm rostral)
Number of subjects: 15
Study 39762947 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical depressive symptoms (DepS)
Number of subjects: 131
Study 39762947 — intervention group
Group type: COMPARATOR
Intervention: No subclinical depressive symptoms (NoDepS)
Number of subjects: 131
Study 39762953 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground robotic exoskeleton (ORE)
Number of subjects: 149
Study 39762953 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 149
Study 39762954 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation using in-house software for vessel area and diameter extraction
Number of subjects: 30
Study 39762954 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 30
Study 39762958 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I analysis using Siemens Healthineers Atellica VTLi
Number of subjects: 2000
Study 39762958 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analyses (random forest, logistic regression, gradient boosting)
Number of subjects: 2000
Study 39762976 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging-based intervention focused on HIV and STI prevention
Number of subjects: 0
Study 39762976 — intervention group
Group type: COMPARATOR
Intervention: Generic HIV education program promoting a healthy lifestyle
Number of subjects: 0
Study 39762978 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted kidney transplantation (RAKT)
Number of subjects: 106
Study 39762978 — intervention group
Group type: COMPARATOR
Intervention: Open kidney transplantation (OKT)
Number of subjects: 106
Study 39762986 — intervention group
Group type: EXPERIMENTAL
Intervention: PSG-assisted commencement of NIV settings
Number of subjects: 244
Study 39762986 — intervention group
Group type: COMPARATOR
Intervention: Sham PSG
Number of subjects: 244
Study 39763002 — intervention group
Group type: EXPERIMENTAL
Intervention: RS3 condition (Rural School Support Strategies)
Number of subjects: 40
Study 39763002 — intervention group
Group type: COMPARATOR
Intervention: Basic supports condition (standard trainings)
Number of subjects: 40
Study 39763004 — intervention group
Group type: EXPERIMENTAL
Intervention: Archetype development methodology for primary care champions
Number of subjects: 0
Study 39763004 — intervention group
Group type: EXPERIMENTAL
Intervention: Archetype development methodology for advance care planning facilitators
Number of subjects: 0
Study 39763004 — intervention group
Group type: EXPERIMENTAL
Intervention: Archetype development methodology for patients
Number of subjects: 0
Study 39763004 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy and challenges between archetypes
Number of subjects: 0
Study 39763142 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-Together (self-directed intervention with a workbook and 6 booklets)
Number of subjects: 48
Study 39763142 — intervention group
Group type: COMPARATOR
Intervention: Coping-Together + lay telephone guidance
Number of subjects: 48
Study 39763142 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-up intervention in Stage 2
Number of subjects: 48
Study 39763430 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC/F/TAF
Number of subjects: 21
Study 39763430 — intervention group
Group type: COMPARATOR
Intervention: DRV/c/F/TAF
Number of subjects: 21
Study 39763513 — intervention group
Group type: EXPERIMENTAL
Intervention: MIMIC intervention (including triage cards, pocket cards, online training module, patient educational pamphlets, and clinical champions)
Number of subjects: 64
Study 39763581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levocarnitine (20 mg/kg body weight, infused over 2-3 min after each hemodialysis session for 24 weeks)
Number of subjects: 83
Study 39763581 — intervention group
Group type: COMPARATOR
Intervention: Oral levocarnitine (500 mg three times daily for 24 weeks)
Number of subjects: 83
Study 39763591 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-02
Number of subjects: 196
Study 39763591 — intervention group
Group type: COMPARATOR
Intervention: GV (gel vehicle, placebo)
Number of subjects: 196
Study 39763591 — intervention group
Group type: COMPARATOR
Intervention: NSSOC (non-surgical standard of care)
Number of subjects: 196
Study 39764085 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner Engineering program (Shambhavi Mahamudra Kriya)
Number of subjects: 290
Study 39764090 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 0
Study 39764090 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard eating patterns)
Number of subjects: 0
Study 39764092 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention to increase paretic propulsion and reduce propulsion asymmetry.
Number of subjects: 0
Study 39764092 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 39764095 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian dysfunction
Number of subjects: 0
Study 39764095 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39764100 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative eribulin (1.1 mg/m² for three 21-day cycles)
Number of subjects: 0
Study 39764100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 0
Study 39764115 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Management Checkups
Number of subjects: 0
Study 39764289 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg every 4 weeks on top of standard of care (SOC) treatment (atorvastatin 40 mg/day and ezetimibe 10 mg/day)
Number of subjects: 120
Study 39764289 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment (atorvastatin 40 mg/day and ezetimibe 10 mg/day)
Number of subjects: 120
Study 39764289 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg every 4 weeks
Number of subjects: 120
Study 39764567 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy (PT) - two 25 mg doses administered orally with psychological support
Number of subjects: 59
Study 39764567 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram treatment (ET) - 6-week course with daily doses of 10 mg for three weeks and 20 mg for the subsequent three weeks plus matched psychological support
Number of subjects: 59
Study 39764571 — intervention group
Group type: EXPERIMENTAL
Intervention: Health apps with gamification
Number of subjects: 10079
Study 39764571 — intervention group
Group type: COMPARATOR
Intervention: Non-gamified health apps (control)
Number of subjects: 10079
Study 39764800 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based breastfeeding education
Number of subjects: 120
Study 39764800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no web-based education)
Number of subjects: 120
Study 39765128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension treatments
Number of subjects: 47
Study 39765160 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-VG intervention
Number of subjects: 84
Study 39765160 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 84
Study 39765425 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping and nerve tendon gliding exercises
Number of subjects: 90
Study 39765425 — intervention group
Group type: COMPARATOR
Intervention: Night splint and nerve tendon gliding exercises
Number of subjects: 90
Study 39765425 — intervention group
Group type: COMPARATOR
Intervention: Nerve tendon gliding exercises
Number of subjects: 90
Study 39765426 — intervention group
Group type: EXPERIMENTAL
Intervention: MyotonPRO measurements of biomechanical properties (tone, stiffness, elasticity) of the abductor pollicis brevis and flexor pollicis brevis muscles
Number of subjects: 55
Study 39765426 — intervention group
Group type: EXPERIMENTAL
Intervention: MyotonPRO measurements of elasticity (logarithmic decrement)
Number of subjects: 55
Study 39765426 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinch strength assessment using Baseline pinch gauge
Number of subjects: 55
Study 39765937 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Intervention
Number of subjects: 0
Study 39765937 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39766323 — intervention group
Group type: EXPERIMENTAL
Intervention: dihexanoyl-phosphatidyl-THIO (diC6-THIO)
Number of subjects: 0
Study 39767014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement consisting of 400 mg of a standardized extract of the persimmon fruit
Number of subjects: 0
Study 39767014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39767944 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent assessment of cervical spine rotation preference
Number of subjects: 69
Study 39767944 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician assessment of cervical spine rotation preference
Number of subjects: 69
Study 39767944 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective assessment of cervical range of motion using IMUs
Number of subjects: 69
Study 39768384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic serum containing niacinamide, postbiotics, and peptides
Number of subjects: 25
Study 39768384 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 39768420 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide and Dapagliflozin combination
Number of subjects: 0
Study 39768420 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitor (DPP-4i)
Number of subjects: 0
Study 39768590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrates
Number of subjects: 0
Study 39768590 — intervention group
Group type: COMPARATOR
Intervention: Fresh Frozen Plasma
Number of subjects: 0
Study 39768590 — intervention group
Group type: COMPARATOR
Intervention: Albumin Replacement
Number of subjects: 0
Study 39768667 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter repair
Number of subjects: 0
Study 39768667 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical procedure
Number of subjects: 0